First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
about
Targeting Cell Survival Proteins for Cancer Cell DeathOther targeted drugs in melanomaHeat shock and other apoptosis-related proteins as therapeutic targets in prostate cancerHsp90 as a Potential Therapeutic Target in Retinal DiseaseAdaptive dose-finding studies: a review of model-guided phase I clinical trials.Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsMTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.Synthesis, characterization, and pharmacological evaluation of novel azolo- and azinothiazinones containing 2,4-dihydroxyphenyl substituent as anticancer agents.Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancerHSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemiaPhase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.Efficiency of AUY922 in mice with adult T-cell leukemia/lymphomaMolecular imaging for early prediction of response to Sorafenib treatment in sarcoma.Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.Chemical signatures and new drug targets for gametocytocidal drug development.Hsp90 inhibition protects against inherited retinal degeneration.BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.Advances in HSP27 and HSP90-targeting strategies for glioblastoma.TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.Heat shock protein antagonists in early stage clinical trials for NSCLC.Ocular toxicities of MEK inhibitors and other targeted therapies.The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.Destabilizing RET in targeted treatment of thyroid cancers.Stimulation of electroporation-induced inward currents in glioblastoma cell lines by the heat shock protein inhibitor AUY922.Endothelial cell signaling and ventilator-induced lung injury: molecular mechanisms, genomic analyses, and therapeutic targets.HSP90 as a novel molecular target in non-small-cell lung cancerResponse-adaptive clinical trials: case studies in the medical literature.A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.
P2860
Q26765447-13D0736F-CD16-44C3-BC4F-CACF84B73305Q26775594-B4EED0DE-747D-4E3B-A9EB-639F87DEC9D1Q27026128-1DDC045A-4A85-4987-89D2-D1C9F8811A5FQ28083847-FBD6E154-1E75-4DCE-A3E5-19C0B1E3E610Q34001009-05894A3D-5413-408E-9B89-5E9288676BA4Q34085148-907BB900-12DC-4359-B95D-93704FF0A5F0Q34120364-BF318C54-1B8F-40DB-9EEF-88EA66532801Q34478388-4AA69191-3D00-4513-B49E-BCB653795267Q34564071-C39EA0D4-BBD3-45F2-B81F-4479D48F45BAQ34957090-D217D516-B6EF-4860-8A3C-4DFCA92364CDQ35051987-6E474AF9-63AD-49F0-B2DC-B2722CFBF9BEQ35098333-9BD49669-5D67-46BE-875D-71CB7EDE7461Q35837669-5B6951F0-EA19-495F-86AA-3F9ACBAEBFA3Q35861111-DD167BD8-15CD-4944-AF2E-EBF74445E10DQ35930811-2A9C41A5-7D1A-4EAE-9663-0E2F55B59B9CQ36125976-B595E977-8F4B-4219-9E73-1DF6C96A95B8Q36347106-D1FE5303-597E-4EEC-8976-97509FFC242BQ36436934-379DA128-1594-4F1D-A6C0-86E7FBE248DBQ36472987-501DFB4A-3604-4972-9B5A-410846F069D8Q36938818-BB3E3AF4-C060-475F-BE4A-04A797E8DB78Q36999363-AB115326-7E44-4654-9FF5-C49763020B86Q37001967-63467E37-942D-4AF2-B2AC-1A10FB641D0DQ37402623-3927789B-28FB-46A9-BE63-B92367667874Q37437264-51E0DAF9-1534-4E91-9700-9B0E88EFC0B5Q37489274-8FE00ACC-90AB-4AD7-B40B-1ECBC7CAE9B1Q37649115-17642AB0-EF70-4211-AB70-07D4E9C62A2CQ37693266-39862661-2219-4254-907B-DA5DE34B4DF0Q37706134-DC66662D-DB18-48E5-8587-B751122D7BECQ38722149-07491E9D-B019-4568-AAB6-B746BAD0F80FQ38722571-78E9A07B-4EAA-4A53-8275-ADB59453AAEEQ38748687-A74CF458-B19A-4C5C-A274-D1B01281C1F7Q38764273-4469902A-7A57-4D23-8690-75F04E6925EDQ38767329-7FC22BF1-8935-4CD6-9BCD-0CFA05DCB4BAQ38785352-3CB1198C-3B56-4E89-9428-960EBE6811C0Q38819099-A22F8EC0-6784-4329-82A6-93CFA8C0BE7FQ38987125-5ADBA670-BB00-4E49-8EE2-3657EFCC7080Q39040020-042E7FF5-EBA4-402F-968F-9544BF4DB0C1Q39139943-F20CC91A-6452-47B1-82DC-98B724732FA9Q39300281-E66047E5-F05D-4408-BF60-B9C9CF9858C9Q40666673-3D8F8F58-A363-422E-A92C-3DCA10538AE9
P2860
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
First-in-human phase I dose-es ...... ts with advanced solid tumors.
@en
First-in-human phase I dose-es ...... ts with advanced solid tumors.
@nl
type
label
First-in-human phase I dose-es ...... ts with advanced solid tumors.
@en
First-in-human phase I dose-es ...... ts with advanced solid tumors.
@nl
prefLabel
First-in-human phase I dose-es ...... ts with advanced solid tumors.
@en
First-in-human phase I dose-es ...... ts with advanced solid tumors.
@nl
P2093
P1476
First-in-human phase I dose-es ...... ts with advanced solid tumors.
@en
P2093
Carolyn Britten
Cornelia Quadt
Cristiana Sessa
Cristina Fernandez-Ibarra
Geoffrey I Shapiro
Kapil N Bhalla
Karen S Jacks
Mikhail Akimov
Monica Mita
P304
P356
10.1158/1078-0432.CCR-12-3404
P407
P50
P577
2013-06-11T00:00:00Z